3Dresyns provides formulation and process consulting to support controlled material selection, printer setup and print/wash/post-cure workflows for biomedical development. Target endpoints may include high polymer conversion and reduced residuals, by-products, extractables or leachables under defined conditions. Final safety, biological suitability and regulatory compliance must be validated by the device manufacturer for the intended use.
Why biomedical development requires protocols and process control
Risk management depends on both material design and manufacturing-process control. Printer/light-source performance, cleaning, post-curing, contamination control and release criteria should be defined, monitored and validated for the specific device and workflow.
Where residual constituents or process contaminants are relevant, removal and acceptance criteria should be addressed during validated post-processing and, where applicable, sterilization before final use.
Risk context: extractables, leachables, residuals, and byproducts
Detailed printing, post-curing and post-processing protocols can support control of extractables, leachables, residuals and by-products. The final device manufacturer is responsible for determining whether the complete workflow meets the applicable safety, biological-evaluation and regulatory requirements for the intended biomedical or food-contact application.
3Dresyns consulting services
Advanced 3D printing resins and technical expertise for medical, dental and industrial additive manufacturing.